Charlie Dong, PhD
Professor of Biochemistry, Molecular Biology & Pharmacology
Adjunct Professor, School of Informatics and Computing
- xcdong@iu.edu
- Phone
- 317-278-1097
- Address
-
635 Barnhill Drive
Medical Science, Room MS1021D
Indianapolis, IN 46202 - PubMed:
-
Bio
X. Charlie Dong, PhD, is a professor in the Department of Biochemistry, Molecular Biology and Pharmacology and an investigator at the Indiana University Center for Diabetes and Metabolic Diseases. Prior to his appointment at Indiana University, he received his B.S. in Biology from Shandong Normal University, M.S. in Genetics from Chinese Academy of Sciences Institute of Genetics and Developmental Biology, and Ph.D. in Molecular and Cellular and Developmental Biology from the Ohio State University. He also received postdoctoral training in diabetes and metabolism from Joslin Diabetes Center and Boston Children's Hospital at Harvard Medical School. He was promoted to instructor in pediatrics at Harvard Medical School before joining Indiana University.
Key Publications
A complete list of published work is available.
Cho JH, Kim HG, Huang M, Wang S, Liu S, Lu A, Zhang Y, Fang Z, Liu W, Wan J, Dong XC. The PNPLA3 148M variant exacerbates the alcohol-induced liver injury and tumorigenesis in mice. Am J Pathol. 2026 Jan;196(1):209-222.
Hazari Y, Habbouche L, Lopez VAG, Urra H, Diaz J, Tamburini G, Milani M, Durand S, Aprahamian F, Baxter R, Huang M, Dong XC, Gonzalez-Rojas L, Silva JF, Tapia-Dufey I, Vihinen H, Ratziu V, Foufelle F, Hengstler JG, Jokitalo E, Maiers JL, Plate L, Kroemer G, Bailly-Maitre B, Hetz C. Targeting the ER stress sensor IRE1 protects the liver from fibrosis through the downregulation of the proteostasis factor P4HB/PDIA1. Hepatology 2026 Jan 1;83(1):75-93.
Park J, Lokuge SD, Huang M, Wang S, Liang J, Katturajan R, Marakovits C, Wan J, Dong XC. SIRT6 is a key regulator of pancreatic β-cell survival and function during aging. Diabetes. 2025 Nov 1;74(11):1976-1991.
Kim HG, Huang M, Wang S, Zhang Y, Liu S, Dong C, Yang X, Cho JH, Chowdhury K, Stein BD, Wan J, Dong XC. Autophagy related 14 protects against liver injury by inhibiting multiple cell death pathways. eGastroenterology. 2025 Oct 13;3(4):e100181.
Yang Z, Liu Z, Liu W, Dong XC. Steatotic liver disease and cancer: from pathogenesis to therapeutic targets. eGastroenterology. 2025 Sep 12;3(3):e100218.
Xia F, Shi S, Palacios E, Liu W, Buscho SE, Li J, Huang S, Vizzeri G, Dong XC, Motamedi M, Zhang W, Liu H. Sirt6 protects retinal ganglion cells and optic nerve from degeneration during aging and glaucoma. Mol Ther. 2024 Apr 24:S1525-0016(24)00253-3.
Huang M, Zhang Y, Park J, Chowdhury K, Xu J, Lu A, Wang L, Zhang W, Ekser B, Yu L, Dong XC. ATG14 plays a critical role in hepatic lipid droplet homeostasis. Metabolism. 2023 Sep 22;148:155693. [PMID: 37741434]
Dong XC. Sirtuin 6-A Key Regulator of Hepatic Lipid Metabolism and Liver Health. Cells. 2023 Feb 19;12(4):663. [PMID: 36831330]
Chowdhury K, Huang M, Kim HG, Dong XC. Sirtuin 6 protects against hepatic fibrogenesis by suppressing the YAP and TAZ function. FASEB J. 2022 Oct;36(10)e22529. [PMID: 36036554]
Tao Z, Shi L, Parke J, Zheng L, Gu W, Dong XC, Liu D, Wang, Z, Olumi AF, Cheng Z. Sirt1 coordinates with ERα to regulate autophagy and adiposity. Cell Death Discov. 2021 Mar 15;7(1):53. [PMID: 33723227]
Fang Z, Kim HG, Huang M, Chowdhury K, Li MO, Liangpunsakul S, Dong XC. Sestrin proteins protect against lipotoxicity-induced oxidative stress in the liver via suppression of C-Jun N-terminal kinases. Cell Mol Gastroenterol Hepatol. 2021 May 4:S2352-345X(21)00086-2. [PMID: PMID: 33962074]
Misra J, Holmes MJ, Mirek ET, Langevin M, Kim HG, Carlson KR, Watford M, Dong XC, Anthony TG, Wek, RC. Discordant regulation of eIF2 kinase GCN2 and mTORC1 during nutrient stress. Nucleic Acids Res. 2021 Jun 4;49(10):5726-5742. [PMID: 34023907]
Dong XC. PNPLA3-A Potential Therapeutic Target for Personalized Treatment of Chronic Liver Disease. Front Med (Lausanne). 2019 Dec 17;6:304. doi: 10.3389/fmed.2019.00304. eCollection 2019. Review.
Vemuri S, Srivastava R, Mir Q, Hashemikhabir S, Dong XC, Janga SC. SliceIt: A genome-wide resource and visualization tool to design CRISPR/Cas9 screens for editing protein-RNA interaction sites in the human genome. Methods. 2019 Sep 5. pii: S1046-2023(19)30111-2. doi: 10.1016/j.ymeth.2019.09.004. [Epub ahead of print]
Liu Y, Kim HG, Dong E, Dong C, Huang M, Liu Y, Liangpunsakul S, Dong XC. Sesn3 deficiency promotes carcinogen-induced hepatocellular carcinoma via regulation of the hedgehog pathway. Biochim Biophys Acta Mol Basis Dis. 2019 Oct 1;1865(10):2685-2693. doi: 10.1016/j.bbadis.2019.07.011. Epub 2019 Jul 24.
Kim HG, Huang M, Xin Y, Zhang Y, Zhang X, Wang G, Liu S, Wan J, Ahmadi AR, Sun Z, Liangpunsakul S, Xiong X, Dong XC. The epigenetic regulator SIRT6 protects the liver from alcohol-induced tissue injury by reducing oxidative stress in mice. J Hepatol. 2019 Nov;71(5):960-969. doi: 10.1016/j.jhep.2019.06.019. Epub 2019 Jul 8.
Huang M, Kim HG, Zhong X, Dong C, Zhang B, Fang Z, Zhang Y, Lu X, Saxena R, Liu Y, Zhang C, Liangpunsakul S, Dong XC. Sestrin 3 Protects Against Diet-Induced Nonalcoholic Steatohepatitis in Mice Through Suppression of Transforming Growth Factor β Signal Transduction. Hepatology. 2020 Jan;71(1):76-92. doi: 10.1002/hep.30820. Epub 2019 Sep 27.
Tao R, Wang C, Stöhr O, Qiu W, Hu Y, Miao J, Dong XC, Leng S, Stefater M, Stylopoulos N, Lin L, Copps KD, White MF. Inactivating hepatic follistatin alleviates hyperglycemia. Nat Med. 2018 Oct;24(10):1628. doi: 10.1038/s41591-018-0129-0.
For a complete list of publications, visit PubMed
| Year | Degree | Institution |
|---|---|---|
| 2002 | PhD | The Ohio State University |
| 1994 | MS | Chinese Academy of Sciences |
| 1991 | BS | Shandong Normal University |
Diabetes and obesity have both reached epidemic proportions in the United States. It is becoming urgent to elucidate the pathological mechanisms of these health problems. Improper gene regulation by transcriptional and epigenetic factors is critically involved in the pathogenesis of these metabolic diseases. Dr. Dong's laboratory investigates genetic and epigenetic regulation of metabolic homeostasis, gene-environment interactions, and metabolic and cellular abberrances. Our research goals are to utilize the state-of-the-art technologies including genomics, epigenomics, proteomics, metabolomics, high-resolution imaging, and genomic editing to elucidate molecular and pathophysiological mechanisms underlying diabetes, obesity, chronic liver diseases and cancer and identify drug targets for the prevention or treatment of those disorders.
Dr. Dong also has interests in human diabetes, obesity, MASLD, MASH, ALD, liver cancer and their pathogenesis and clinical treatment. Precision medicine can be applied to these diseases to promote better diagnosis and therapeutic treatment.
Desc: Showalter Scholar
Scope: School
Date: 2015-07-01